Mallinckrodt Q1 net sales up 10.2% to $467.8M; net loss improves 73.8%

Keenova Therapeutics plc

2024-Q1 EPS reported -$3.32 revenue$467,800,000

Net sales of $467.8M, up 10.2% YoY on a reported and constant currency basis.
Net loss of $65.4M, a 73.8% improvement from $249.3M in prior year quarter.
Adjusted EBITDA $144.9M, up 17.3% YoY from $123.5M.
Acthar Gel net sales $102.8M (+25.4%), Terlivaz $6.0M; Specialty Generics +22.0%.
Full year guidance reaffirmed; SelfJect launch expected in Q3 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.88

Keenova Therapeutics plc reported the first quarter ended March 29, 2024 results: revenue $467.8 million, net income net loss of $65.4 million. Guidance reaffirmed.

Period: the first quarter ended March 29, 2024
Revenue: $467.8 million
Net income: net loss of $65.4 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

in such a filing. --- EX-99.1 (EX-99.1) --- Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance Achieves First Quarter Net Sales of $467.8 Million, Reflecting 10.2% Year-Over-Year Growth on a Reported and Constant Currency Basis Reports Net Loss of $65.4 Million , Reflecting a 73.8% Year-Over-Year Improvement; Delivers

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001567892-24-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.